Consortium - "A group formed to undertake an enterprise beyond the resources of any one member."
Webster's Collegiate Dictionary

     The CLL Research Consortium (CRC) is a multi-institutional program project, funded, in part, by the National Institute of Health. The consortium has brought together institutions that, under normal circumstances, would not engage one another as they currently can under the auspices of CRC. The Consortium includes the following clinical sites: University of California, San Diego; M.D. Anderson Cancer Center, Ohio State University, Long Island Jewish Medical Center, Dana Farber Cancer Institute, Mayo Clinic, and several sites that perform laboratory work alone, including the Burnham Institute and St. Bart's of London. These institutions see a diverse patient population and all possess high quality basic science laboratories. Bringing these sites together in the context of the CRC has resulted in a program that is much more than the sum of its parts.

• Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. 10/2009
• p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy. 10/2009
• Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia. 10/2009
• Chronic lymphocytic leukemia of E{micro}-TCL1 transgenic mice undergoes rapid cell-turnover that can be offset by extrinsic CD257 to accelerate disease progression. 9/2009
• Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. 9/2009
• Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 Years. 9/2009
• Pretreatment angiogenic cytokines predict response to chemoimmunotherapy in patients with chronic lymphocytic leukaemia. 9/2009
• Relative seroprevalence of human herpes viruses in patients with chronic lymphocytic leukaemia. 6/2009
• De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience. 5/2009
• B-Cell Clones as Early Markers for Chronic Lymphocytic Leukemia (3/2009)
• Immune System Altered Years Before CLL Diagnosis (3/2009)
• Validation of an LC-MS based approach for profiling histones in chronic lymphocytic leukemia. (3/2009)
• Computational identification of CDR3 sequence archetypes among immunoglobulin sequences in chronic lymphocytic leukemia. (3/2009)
• The CLLU1 expression level is a stable and inherent feature of the chronic lymphocytic leukemia clone. (3/2009)
• MiRNAs and Cancer. (3/2009)
• Characteristics Associated With Important Clinical End Points in Patients With Chronic Lymphocytic Leukemia at Initial Treatment. (2/2009)
• Mechanism of action of SNS-032, a novel cyclin dependent kinase inhibitor, in chronic lymphocytic leukemia. (2/2009)
• MicroRNAs in the ontogeny of leukemias and lymphomas. (2/2009)
• The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia. (1/2009)
• Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia. (1/2009)
• Chimeric form of tumor necrosis factor-alpha has enhanced surface expression and antitumor activity. (1/2009)

Archives

Those who are interested in providing a monetary gift to the CLL Research Consortium can do so by sending the donation to the CLL Research Consortium Administrative Core Office at the:

University of California, San Diego
CLL Research Consortium
Attn: CRC Administrator
Rebecca and John Moores UCSD Cancer Center
3855 Health Sciences Dr.
La Jolla, Ca, 92037-0820